132036-39-6 Usage
Description
5-[(1-Methylindole-3-yl)carbonyl]-4,5,6,7-tetrahydro-1H-bezimidazole is a complex organic compound with a unique molecular structure that features a bezimidazole core and an indole-based side chain. 5-[(1-Methylindole-3-yl)carbonyl]-4,5,6,7-tetrahydro-1H-bezimidazole exhibits a range of biological activities, making it a promising candidate for various pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
5-[(1-Methylindole-3-yl)carbonyl]-4,5,6,7-tetrahydro-1H-bezimidazole is used as an anti-inflammatory agent for its potential to alleviate inflammation and associated symptoms. Its synergistic anti-itching properties make it particularly useful in the development of treatments for conditions characterized by itching and inflammation, such as dermatitis, eczema, and other skin disorders.
Additionally, due to its unique molecular structure and biological activities, 5-[(1-Methylindole-3-yl)carbonyl]-4,5,6,7-tetrahydro-1H-bezimidazole may also have potential applications in other areas of the pharmaceutical industry, such as pain management, neuroprotection, or as a building block for the development of new drugs with novel mechanisms of action. Further research and development would be required to fully explore and validate these potential uses.
Check Digit Verification of cas no
The CAS Registry Mumber 132036-39-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,2,0,3 and 6 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 132036-39:
(8*1)+(7*3)+(6*2)+(5*0)+(4*3)+(3*6)+(2*3)+(1*9)=86
86 % 10 = 6
So 132036-39-6 is a valid CAS Registry Number.
InChI:InChI=1/C17H17N3O/c1-20-9-13(12-4-2-3-5-16(12)20)17(21)11-6-7-14-15(8-11)19-10-18-14/h2-5,9-11H,6-8H2,1H3,(H,18,19)
132036-39-6Relevant articles and documents
Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. II. Synthesis and structure-activity relationships of 4,5,6,7-tetrahydro-1H-benzimidazole derivatives
Ohta, Mitsuaki,Suzuki, Takeshi,Ohmori, Junya,Koide, Tokuo,Matsuhisa, Akira,Furuya, Toshio,Miyata, Keiji,Yanagisawa, Isao
, p. 1000 - 1008 (2007/10/03)
A novel series of 4,5,6,7-tetrahydro-1H-benzimidazole derivatives 4, 5, 6 and 7 was prepared and evaluated for activities as 5-hydroxytryptamine (5- HT3) receptor antagonists which may be useful for the treatment of irritable bowel syndrome (IBS) as well as nausea and vomiting associated with cancer chemotherapy. These compounds were designed by modifying the aromatic- carbonyl part of N-(2-methoxyphenyl)-4,5,6,7-tetrahydro-1H-5- benzimidazolylcarboxamide 3, leaving the imidazole moiety unchanged as the amine part. The indole derivatives 7d, g, h and indolizine derivatives 7k, 1 were found to be highly potent on the von Bezold-Jarisch (B.J.) reflex test with ID50 values of below 0.1 μg/kg, and the indoline derivative 6c, indole derivatives 7a, d, g, benzofurane derivative 7j and indolizine derivative 7k were observed to be very potent on the colonic contraction with IC50 values of below 0.1 μM. In particular, 71 was the most potent on the B.J. reflex (ID50 = 0.018 μg/kg), approximately 200 and 50 times more potent than ondansetron 1 and granisetron 2, and 7k was the most potent on the colonic contraction (IC50 = 0.011 μM), approximately 70 and 6 times more potent than 1 and 2, respectively.
